NCT01025453View on ClinicalTrials.gov

Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 1, 2009

Primary Completion Date

January 16, 2018

Study Completion Date

January 16, 2018

Conditions
Thyroid Cancer
Interventions
DRUG

Temsirolimus and Sorafenib

Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow

11725

Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack

07920

Memorial Sloan-Kettering at Basking Ridge, Basking Ridge

Unknown

Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

collaborator

Pfizer

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER